Research use only. PT-141 is sold strictly as a reference material for in-vitro and laboratory research. Nothing here is medical advice, a treatment claim, a dosing protocol, or a statement of human efficacy — it summarises how the published literature characterises the peptide at the receptor level. Every batch we list is published with its independent Janoshik HPLC certificate.
What PT-141 is
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and a melanocortin-receptor agonist. It is a metabolite/analog of Melanotan II — the broad melanocortin agonist — but the literature distinguishes them by receptor emphasis: where Melanotan II research centres on MC1R (pigmentation), PT-141 is studied primarily through the MC4R central melanocortin pathway. Understanding that it acts centrally on melanocortin receptors, rather than on the vascular system, is the key to reading its literature correctly.
Mechanism: central, not vascular
The defining point in the PT-141 literature is the contrast with PDE5-type vascular mechanisms. PT-141’s research activity is mediated through central melanocortin (MC4R) signalling in the nervous system, a fundamentally different pathway. This is why it is studied as a melanocortin-pathway tool rather than as a vascular compound — the receptor target, not the downstream readout, is what defines its research class.
What the research investigates
- Melanocortin (MC4R) signalling. The core theme — central melanocortin-receptor activation and its downstream pathways in research models.
- Arousal-pathway research. The strand of literature that gave the compound its research reputation examines central arousal pathways via melanocortin signalling, distinct from peripheral mechanisms.
- Melanocortin-system pharmacology. PT-141 is used as a reference agonist in broader studies of the melanocortin receptor family.
PT-141 vs Melanotan II
Both are melanocortin agonists derived from the same family, but they are studied for different receptor emphases: Melanotan II for MC1R-linked pigmentation research, PT-141 for the MC4R central pathway. They are best read as related tools for different parts of the melanocortin system rather than substitutes.
What the literature does NOT establish
No validated human dosing protocol, no human efficacy or treatment claim, and no long-term safety data are asserted on this page. PT-141 is presented strictly as a melanocortin-receptor research compound; any application to humans is outside the scope of what is sold and what this overview supports. Treat it strictly as a laboratory research compound.
Handling and reconstitution
PT-141 ships as lyophilised powder and must be reconstituted before laboratory work; reconstitution volume sets concentration per unit, so calculate it with our reconstitution guide rather than estimating.
Verifying what you receive
The PT-141 we list is published with the independent Janoshik HPLC certificate that accompanies its batch — see the lab results archive; the task ID resolves on Janoshik’s own domain.
Frequently asked questions
What is PT-141?
A synthetic cyclic heptapeptide (bremelanotide) that acts as a melanocortin-receptor agonist, studied primarily through the central MC4R pathway. It is an analog/metabolite of Melanotan II.
How is PT-141 different from Melanotan II?
Both are melanocortin agonists, but Melanotan II research emphasises MC1R (pigmentation) while PT-141 is studied mainly through the MC4R central pathway.
What pathway does PT-141 act on?
Central melanocortin (MC4R) signalling in the nervous system — distinct from vascular/PDE5-type mechanisms. The receptor target defines its research class.
What is PT-141 researched for?
Melanocortin-system pharmacology and central arousal-pathway research mediated through MC4R signalling, in research models.
How do I verify the purity of the batch I receive?
Each batch we list is published with its independent Janoshik HPLC certificate and a public verify link on Janoshik’s own domain.
Is PT-141 for human use?
No. It is sold strictly as a research-use-only reference material and is not intended for human or veterinary use.
Summary
PT-141 (bremelanotide) is a melanocortin MC4R-agonist research peptide — a Melanotan II analog studied for the central melanocortin pathway rather than pigmentation or vascular mechanisms. Match it to the research question, reconstitute it correctly, and confirm the batch against its published Janoshik certificate.